# Pre-Phase-3 Final Readiness & Integrity Report

**Evaluation Phase:** MediScanAI Phase D.2.c-Final Pre-Phase-3 Audit  
**Date:** October 17, 2026  
**Auditor:** Autonomous Systems Pre-Phase-3 Integrity & Safety Auditor  
**Authorized Final Verdict:**

$$\mathbf{READY\_WITH\_WARNINGS}$$

---

## 1. Executive Summary & Authorizing Decision

This audit conducted an independent, evidence-backed evaluation of the completed Phase D.2.c hybrid retrieval and intent-routing work before authorizing Phase 3 engineering.

The pre-phase audit focused on three mandatory verification checks:
1. **Check 1 — Reconciling Held-Out Retrieval Metrics:** Fully reconciled. The difference between Phase D.2.a ($0.6667$) and Phase D.2.c ($0.5556$) is classified as **`EXPLAINED_BY_RETRIEVAL_CHANGE`**. The calibrated threshold $\tau = -0.5$ in `CFG-04` pruned one low-scoring lay-phrased multi-symptom case (`MED-BENCH-035`) while successfully eliminating false positive retrieval on negative controls (`MED-BENCH-045`), raising rejection accuracy from $0.0$ to $1.0$.
2. **Check 2 — Safety-Suite Overlap and Comparability:** Fully reconciled and classified as **`COMPARABLE_ON_COMMON_SUBSET_ONLY`**. On the identical 12-scenario common subset, Phase D.2.c achieved **12/12 passed (100.0%)** compared to D.1's **9/12 passed (75.0%)**. Historical citations of "2/5" in D.1 represented the 5-case negative control subset, not the total suite. On the expanded 14-scenario suite, Phase D.2.c achieved **14/14 passed (100.0%)**.
3. **Check 3 — Intent-Router Edge-Case Audit:** Read-only testing across 27 edge cases confirmed that the router robustly intercepts novel and known fictional medicines (0% false acceptance). It preserves multi-agent combination therapies without collapsing to monotherapy. However, three bounded, non-critical routing defects were discovered (notably the `"oral"` keyword collision where generic oral liquid formulations misroute to disease diagnostic chunks).

Because all integrity constraints remain satisfied and remaining routing defects are strictly bounded without high-risk false acceptances or safety escalations, Phase 3 is authorized under **`READY_WITH_WARNINGS`**.

---

## 2. Synthesis of the Three Verification Checks

### Check 1: Held-Out Retrieval Metric Reconciliation
- **Classification:** `EXPLAINED_BY_RETRIEVAL_CHANGE`
- **Reconciliation Table:**

| Metric Dimension | Phase D.2.a (`CFG-01`) | Phase D.2.c (`CFG-04`) | Delta ($\Delta$) | Audit Assessment |
| :--- | :---: | :---: | :---: | :--- |
| **Strict Record Recall@5** | **0.6667** (6/9) | **0.5556** (5/9) | -0.1111 | Reconciled: 1 query change (`MED-BENCH-035`) |
| **Strict Record MRR@10** | **0.5370** | **0.5000** | -0.0370 | Recomputed from case rankings |
| **Negative Control Rejection** | **0.0000** (0/1) | **1.0000** (1/1) | **+1.0000** | Critical safety gain (`MED-BENCH-045`) |
| **Canonical-Entity Recall@5** | *Not evaluated* | **0.7778** (7/9) | +0.2222 | Distinct metric: Active substance match |

- **Proof:** In D.2.a, `MED-BENCH-035` (`"missed periods, trouble getting pregnant, and weight gain"`) had top cross-encoder scores between $-0.55$ and $-2.82$. With no threshold, gold `chunk_3001` was returned at rank 3 ($1.0$ hit). In D.2.c, calibrated threshold $\tau = -0.5$ correctly filtered negative control `MED-BENCH-045` (0 items returned), but also filtered `MED-BENCH-035` (0 items returned).

### Check 2: Safety-Suite Overlap and Comparability
- **Classification:** `COMPARABLE_ON_COMMON_SUBSET_ONLY`
- **Cross-Phase Pass Rates:**

| Safety Cohort | Phase D.1 | Phase D.2.a | Phase D.2.b | Phase D.2.c |
| :--- | :---: | :---: | :---: | :---: |
| **Negative Controls (Unsupported Drugs)** | 2 / 5 (40.0%) | 5 / 5 (100.0%) | 5 / 5 (100.0%) | 5 / 5 (100.0%) |
| **Emergency Triage Escalation** | 3 / 3 (100.0%) | 3 / 3 (100.0%) | 3 / 3 (100.0%) | 3 / 3 (100.0%) |
| **Common 12-Scenario Core Subset** | **9 / 12 (75.0%)** | **12 / 12 (100.0%)** | **12 / 12 (100.0%)** | **12 / 12 (100.0%)** |
| **Full Executed Suite** | 9 / 12 (75.0%) | 12 / 12 (100.0%) | 13 / 14 (92.86%) | **14 / 14 (100.0%)** |

- **Proof:** Historical "2/5" in D.1 was the pass rate on the 5 negative control cases, where `SR-01`, `SR-02`, and `SR-03` failed due to absent upstream entity gating. Standardization in D.2.a resolved all 5. Expansion in D.2.b added `SAF-13` and `SAF-14`. Normalization in D.2.c resolved `SAF-13`.

### Check 3: Intent-Router Normalization Edge Cases
- **Verdict:** `DEFECTS_IDENTIFIED_NONCRITICAL_ROUTING`
- **Total Tested:** 27 cases
  - **Passed:** 21 cases (77.8%)
  - **Acceptable Fallback / Degradation:** 3 cases (11.1%)
  - **Routing Mismatches / Defect Flags:** 3 cases (11.1%)
  - **Critical Safety / Hallucination Leaks:** **0 cases (0.0%)**
- **Core Findings:**
  1. *Fictional Drug Resistance:* Fictional entities (`Zephastin`, `Virokine`, `Pulmoflux`, `Zorvaxil`, `Cardioprex`, `Faketrol`) are 100% intercepted by the upstream lexical gate and cleanly abstain.
  2. *Combination Preservation:* Multi-drug inputs (`Metformin and Glipizide`, `Metformin / Sitagliptin`, `Lisinopril with Hydrochlorothiazide`) are never collapsed into monotherapies.
  3. *Identified Defects:*
     - **Defect 1 (`DEFECT-ORAL-ROUTE-COLLISION`):** Standalone word `"oral"` in symptom catalog causes generic liquid formulations (`Metformin oral solution`, `Amoxicillin oral suspension`) to route to disease index.
     - **Defect 2 (`DEFECT-SPACE-SEPARATED-STRENGTH`):** Space-separated dosages (`"500 mg"`) leave `"500"` unstripped, falling back to balanced multi-retrieval.
     - **Defect 3 (`DEFECT-SUBSTRING-COLLISION`):** Substring match in lexical gate allows `"met"` to pass gate rather than cleanly abstaining.

---

## 3. Strict Integrity Verification

Every absolute restriction was monitored and verified:

| Invariant / Restriction | Target Requirement | Verified Status | Evidence |
| :--- | :--- | :---: | :--- |
| `entity_resolution/` Access | **Strictly Off-Limits** | **PASSED** | 0 reads, 0 writes, 0 references |
| `evaluation/benchmark/gold_judgments.jsonl` | **Exactly 0 bytes** | **PASSED** | Verified: exactly `0` bytes |
| Production Code Modification (`app/`, `backend/`) | **Zero modifications** | **PASSED** | `git status` confirms 0 production edits |
| Source Datasets & FAISS Indexes | **Zero modifications** | **PASSED** | Untouched |
| Prior Phase Artifacts (D.0, D.1, D.2.a-c) | **No overwrites** | **PASSED** | All prior artifacts preserved intact |
| Cloud API Calls & Paid External Judges | **Zero external calls** | **PASSED** | 100% local deterministic execution |
| Held-Out Test Tuning & Re-Evaluation | **No unauthorized runs** | **PASSED** | Audited existing artifacts |

---

## 4. Specific Warnings and Actionable Scope for Phase 3

While Phase 3 is authorized to proceed, engineering must remediate the following bounded warnings during initial Phase 3 implementation:

1. **Warning W-01: Exclude Common Clinical Administration Routes from Symptom Lexicon**
   - *Problem:* Generic liquid formulations containing `"oral"` misroute to `RETRIEVE_DISEASE_CHUNKS`.
   - *Phase 3 Action:* Filter administration route terms (`"oral"`, `"topical"`, `"otic"`, `"ophthalmic"`) out of `self.symptom_phrases` during catalog loading.
2. **Warning W-02: Support Whitespace in Strength Token Normalization**
   - *Problem:* Regex `^\d+(?:mg|mcg|g|ml)$` misses space-separated doses (`500 mg`).
   - *Phase 3 Action:* Normalize multi-token dosages into unified tokens prior to formulation stripping.
3. **Warning W-03: Whole-Word Token Matching in Lexical Verification Gate**
   - *Problem:* Substring check `primary_token in d_name` allows partial prefixes (`met`) to pass.
   - *Phase 3 Action:* Require exact word-boundary token matching (`\b<token>\b`) against catalog names.
4. **Warning W-04: Cross-Encoder Threshold Calibration for Multi-Symptom Lay Phrasing**
   - *Problem:* Fixed text threshold $\tau = -0.5$ pruned valid gold evidence on `MED-BENCH-035`.
   - *Phase 3 Action:* In Phase 3 passage generation and reranking, explore channel-specific or margin-based adaptive calibration for lay-phrased multi-symptom queries.

---

## 5. Audit Deliverable Directory Manifest

All audit deliverables have been generated in `evaluation/retrieval/phase_d_2_c_final_audit/`:

1. `held_out_metric_reconciliation.md`: Complete mathematical proof and reconciliation of Check 1.
2. `held_out_case_comparison.csv`: Case-by-case 10-query comparison of rankings, scores, and status.
3. `safety_suite_inventory.csv`: Complete cross-phase mapping of all 14 safety scenarios across D.1 to D.2.c.
4. `safety_comparability_report.md`: Denominator deconstruction and common-subset evaluation for Check 2.
5. `intent_router_edge_cases.jsonl`: Detailed execution logs of 27 edge-case queries for Check 3.
6. `intent_router_audit.md`: In-depth analysis of router normalization, entity preservation, and defects.
7. `integrity_report.json`: Machine-readable integrity certification and invariant tracking.
8. `final_readiness_report.md`: Master readiness determination and authorizing decision.
9. `README.md`: Directory overview and navigation index.
